Category Archives: 2014

Prostatesnatchers: A Must-Read Website.

Not long ago, I came across a website called Prostatesnatchers, written by a prominent West coast urologist, Dr. Mark Scholz and Ralph Blum.  Recent posts addressed such topics as:  a) radiation for PSA-relapsed prostate cancer; an alternative to lifelong Lupron more »

Posted in 2014 | Leave a comment

Christmas and New Year thoughts

It’s Christmas 2014 and a New Year 2015!!!  The time of year when a man’s thoughts turn to prostate cancer, right?  Unfortunately, it seems that is true for those of us who have this condition.  Just recently, I saw an more »

Posted in 2014 | Leave a comment

Current Clinical Trials in Immunotherapy for Prostate Cancer.

The Prostate Cancer Research Institute (PCRI) has listed four (4) Phase 2 or Phase 3 clinical trials which are currently recruiting patients.  These trials all involve immunotherapeutic agents. The first is a Phase 3 trial of ProstAtak® coupled with standard more »

Posted in 2014 | Leave a comment

News from Johns Hopkins on Urinary Incontinence, Kegel Exercises and Familial Prostate Cancer.

Urinary incontinence is a major complication of radical prostatectomy.  According to the November 9th Johns Hopkins Health Alerts (Prostate Disorders), incidence of serious incontinence from surgery at medical centers of excellence is low, around 3% whereas from overall national patient more »

Posted in 2014 | Leave a comment

  In  our current disposable society, I am sure that we can all think about specific items that we would have no use for or difficult times in our lives that we would rather not re-live.  But the truth is more »

Posted on by bjgabrielsen | Leave a comment

Four Experts Recommend the Earlier Use of Provenge in Metastatic Prostate Cancer.

In  the last few years, several new therapeutic agents have been approved for treating various aspects of prostate cancer.  Now research also needs to focus on the timely utilization of these agents either individually or in combination and at which more »

Posted in 2014 | Leave a comment

1) A “Calculator” to Predict Biopsy Outcomes; 2) Understanding the TNM Staging System Upon Prostate Cancer Diagnosis.

1) Researchers at the University of Texas Health Sciences Center in San Antonio have developed a “calculator” to predict probabilities of biopsy results based upon data such as PSA, age, race, results of digital examination and family history.  To access more »

Posted in 2014 | Leave a comment

Monitoring Emergence of Treatment-Resistant Prostate Cancer by Measuring Circulating Tumor DNA Levels.

Androgen deprivation (hormonal) therapy is often administered to men with advanced prostate cancer.  However, after a period of time genetic mutations can occur in the prostate cells which then promote tumor growth.  A new way to monitor how a man’s more »

Posted in 2014 | Leave a comment

Recommendations for Men Whose Tumors Have Become Resistant to Hormone Therapy.

Testosterone (androgen)-depleting therapies are usually the first line of defense for men with newly-diagnosed or recurrent prostate cancer. But resistance to these therapies develop over time which leaves the patient and physicians with a number of choices as to the more »

Posted in 2014 | Leave a comment

Disappointing Prostate Cancer Phase III Results for Cabozantinib.

Exelixis, the biotechnology firm developing the metastatic medullary thyroid cancer drug, cabozantinib, in the treatment of a variety of cancers, recently announced disappointing Phase III clinical trial results for the use of cabozantinib in the treatment of metastatic,  hormone-resistant (refractory) more »

Posted in 2014 | 1 Comment